Literature DB >> 22206249

CD248: reviewing its role in health and disease.

Yanet Valdez1, Margarida Maia, Edward M Conway.   

Abstract

CD248, also known as endosialin or tumor endothelial marker-1 (TEM-1), is a C-type lectin-like domain (CTLD) containing cell surface glycoprotein that is expressed by stromal cells of proliferating tissues during embryogenesis and postnatally in tumors and inflammatory lesions. Loss-of-function studies in mice support the notion that CD248 promotes tumor growth and inflammation, observations that are stimulating interest in evaluating this molecule as a therapeutic target. In spite of these advances, the mechanisms by which CD248 modulates cancer and inflammation remain largely enigmatic. This review highlights our current understanding of CD248, its structure, pattern of expression, regulation and function in various disease processes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22206249     DOI: 10.2174/138945012799424615

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  20 in total

1.  Characterization and angiogenic potential of human neonatal and infant thymus mesenchymal stromal cells.

Authors:  Shuyun Wang; Lakshmi Mundada; Sean Johnson; Joshua Wong; Russell Witt; Richard G Ohye; Ming-Sing Si
Journal:  Stem Cells Transl Med       Date:  2015-02-23       Impact factor: 6.940

2.  Genomic landscape of pancreatic neuroendocrine tumors.

Authors:  Niklas Gebauer; Christian Schmidt-Werthern; Veronica Bernard; Alfred C Feller; Tobias Keck; Nehara Begum; Dirk Rades; Hendrik Lehnert; Georg Brabant; Christoph Thorns
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

3.  Molecular remodeling of adipose tissue is associated with metabolic recovery after weight loss surgery.

Authors:  Annie Bouchard-Mercier; Juan de Toro-Martín; Mélanie Nadeau; Odette Lescelleur; Stéfane Lebel; Denis Richard; Laurent Biertho; André Tchernof; Marie-Claude Vohl
Journal:  J Transl Med       Date:  2022-06-23       Impact factor: 8.440

4.  Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Authors:  Ann-Marie Chacko; Chunsheng Li; Madhura Nayak; John L Mikitsh; Jia Hu; Catherine Hou; Luigi Grasso; Nicholas C Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

5.  Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.

Authors:  Emily Capone; Enza Piccolo; Imma Fichera; Paolo Ciufici; Daniela Barcaroli; Arturo Sala; Vincenzo De Laurenzi; Valentina Iacobelli; Stefano Iacobelli; Gianluca Sala
Journal:  Oncotarget       Date:  2017-07-22

6.  TGFβ-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells.

Authors:  Sahana Suresh Babu; Yanet Valdez; Andrea Xu; Alice M O'Byrne; Fernando Calvo; Victor Lei; Edward M Conway
Journal:  BMC Cancer       Date:  2014-02-20       Impact factor: 4.430

7.  Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis.

Authors:  Stuart William Smith; Adam Paul Croft; Hannah Louise Morris; Amy Jane Naylor; David Leonard Huso; Clare Marie Isacke; Caroline Olivia Susan Savage; Christopher Dominic Buckley
Journal:  Nephron       Date:  2015-12-04       Impact factor: 2.847

8.  Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.

Authors:  Katherine Rybinski; Hongxia Z Imtiyaz; Barrie Mittica; Brian Drozdowski; James Fulmer; Keiji Furuuchi; Shawn Fernando; Marianne Henry; Qimin Chao; Brad Kline; Earl Albone; Jason Wustner; JianMin Lin; Nicholas C Nicolaides; Luigi Grasso; Yuhong Zhou
Journal:  Oncotarget       Date:  2015-09-22

9.  Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.

Authors:  Paola Di Benedetto; Vasiliki Liakouli; Piero Ruscitti; Onorina Berardicurti; Francesco Carubbi; Noemi Panzera; Salvatore Di Bartolomeo; Giuliana Guggino; Francesco Ciccia; Giovanni Triolo; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2018-10-03       Impact factor: 5.156

Review 10.  Pericytes, an overlooked player in vascular pathobiology.

Authors:  David Ferland-McCollough; Sadie Slater; Jai Richard; Carlotta Reni; Giuseppe Mangialardi
Journal:  Pharmacol Ther       Date:  2016-12-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.